Kyorin and Acadia enter distribution agreement for Daybue in Japan
ACAD•Kyorin and Acadia Pharmaceuticals entered a distribution agreement for Daybue Stix (trofinetide) for Rett syndrome in Japan. Kyorin will pay Acadia $30 million upfront, with milestone payments of up to $45 million tied to NHI price listing and net sales targets, plus other payments.




